CLL-IPI (chronic lymphocytic leukaemia prognostic index)
CLL-IPI scores five things at diagnosis (TP53 loss or mutation, unmutated IGHV, raised beta-2 microglobulin, advanced stage and age over 65) to predict time to first treatment and survival; TP53 and IGHV are the two that still change which drug is chosen, because they decide whether chemo-immunotherapy is ever an option.
Overview
What is measured: prognosis in chronic lymphocytic leukaemia. How: CLL-IPI (2016) gives 4 points for del(17p) or TP53 mutation, 2 for unmutated IGHV, 2 for serum beta-2 microglobulin above 3.5 mg/L, 1 for Binet B or C (Rai I to IV) and 1 for age over 65, giving low (0 to 1), intermediate (2 to 3), high (4 to 6) and very high (7 to 10) risk with five-year survival of about 93, 79, 63 and 23 percent in the derivation data. Inputs: FISH for del(17p), TP53 sequencing, IGHV sequencing (under 98 percent identity to germline means mutated), serum beta-2 microglobulin and clinical staging. What a result changes: the score does not itself start treatment (the iwCLL criteria do); early-stage high-risk patients have been offered trials (CLL12 tested ibrutinib in early stage and delayed progression without improving survival); del(17p) or TP53 mutation rules out chemo-immunotherapy such as FCR for good, favouring continuous BTK inhibitors or venetoclax with obinutuzumab; unmutated IGHV predicts shorter remissions after fixed-duration therapy and is retested rarely because it does not change. Where it matters: CLL, treatment-naive.
Similar pages
not linked directly; found by shared links- TrialAMPLIFY
Shares IGHV mutational status, del(17p) / TP53 aberration in CLL, Acalabrutinib, Obinutuzumab.
- TrialA Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Shares Acalabrutinib, Obinutuzumab, Chronic lymphocytic leukaemia, first treatment, Venetoclax.
- TrialA Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Shares Acalabrutinib, Obinutuzumab, Chronic lymphocytic leukaemia, first treatment, Venetoclax.
- PairingCaution: chemoimmunotherapy in del(17p)/TP53 CLL
Shares del(17p) / TP53 aberration in CLL, Zanubrutinib, Chronic lymphocytic leukaemia, first treatment, Venetoclax.
- PairingCaution: ibrutinib in patients with cardiac risk
Shares Zanubrutinib, Acalabrutinib, Ibrutinib, Chronic lymphocytic leukaemia, first treatment.
- TrialA Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Shares Zanubrutinib, Acalabrutinib, Chronic lymphocytic leukaemia, first treatment, Venetoclax.
- IdeaMRD-guided treatment duration in CLL
Shares IGHV mutational status, Zanubrutinib, Chronic lymphocytic leukaemia, first treatment, Venetoclax.
- TrialGLOW
Shares Obinutuzumab, Ibrutinib, Chronic lymphocytic leukaemia, first treatment, Venetoclax.